Beyond Air (XAIR) Current Deferred Revenue (2019 - 2026)

Beyond Air (XAIR) reported Current Deferred Revenue of $777000.0 for Q1 2026, down 7.61% sequentially from $841000.0 in Q4 2025.

Beyond Air (XAIR) Current Deferred Revenue (2019 - 2026) Analysis & Trends

Beyond Air (XAIR) has 4 years of Current Deferred Revenue data on file, last reported at $777000.0 in Q1 2026.

For the quarter ending Q1 2026, Current Deferred Revenue changed N/A year-over-year to $777000.0; the trailing twelve-month figure through Mar 2026 stood at $777000.0 (changed N/A YoY), and the FY2026 full-year result was $777000.0, changed N/A from the prior year.
Current Deferred Revenue declined to $777000.0 in Q1 2026, from $841000.0 in the prior quarter.
In the past five years, Current Deferred Revenue ranged from a high of $841000.0 in Q4 2025 to a low of $777000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-
10	Beyond Air	2.25 Mn	-10.02 Mn	94,000.00

Download Data